# Clinical Pharmacogenetic Study of Sorafenib in Egyptian Patients With Hepatocellular Carcinoma

> **NCT06527495** · PHASE1,PHASE2 · RECRUITING · sponsor: **Assiut University** · enrollment: 150 (estimated)

## Conditions studied

- HCC
- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT06527495
- **Lead sponsor:** Assiut University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-01-01
- **Primary completion:** 2024-12-01
- **Final completion:** 2024-12-01
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2024-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06527495

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06527495, "Clinical Pharmacogenetic Study of Sorafenib in Egyptian Patients With Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06527495. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*